Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rennes University Hospital
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• patients with metastatic ccRCC

• Underwent nephrectomy at the University Hospital of Rennes

• treated by sunitinib first line treatment

Exclusion Criteria:

• translocation renal cell carcinoma

• other targeted therapies before the sunitinib